Business
German cannabis imports growing as Canada’s leading share wanes
Germany imported a record amount of cannabis for medical sales and scientific use in the first half of this year, putting the European Union’s biggest market on pace to match or possibly surpass 2021’s total.
The data paints a picture of a medical market that is growing consistently, though not at the blistering pace some analysts had forecast amid the cannabis stock market mania of 2018-20.
Separate data also shows Canada’s role as the country’s top supplier has waned as competition to supply the prized, if still small, German market intensifies.
Cannabis companies in Denmark, the Netherlands and Portugal also supply the German market.
Imports of dried flower and extracts through the first six months of 2022 equaled 10,487 kilograms (11.6 tons), which is 6.1% higher than the first half of last year, when 9,840 kilograms were imported, according to the data from the Federal Institute for Drugs and Medical Devices (BfArM).
Dried cannabis is accounted for as a weight in kilograms, while extracts weight is calculated as the amount of dried flower used for the production of the imported extracts.
In all of 2021, Germany imported 20,589 kilograms of cannabis for medical and scientific purposes, a substantial increase over its 13,346 kilograms in 2020.
Germany imported roughly 8,057 kilograms of cannabis in 2019.
Experts say an unknown quantity of the imported product is reexported to other Europe Union countries, so the import figure should not be used to measure Germany’s market size.
Canada being challenged
Canada remained Germany’s top supplier in 2021, separate German government data shows.
Last year, Canadian licensed producers shipped 6,493 kilograms of medical cannabis flower and extracts to Germany, accounting for approximately one-third of the country’s imports.
However, that percentage is falling.
Canada has accounted for upward of 38% of all of Germany’s medical cannabis imports since 2017, according to a report by Der Spiegel newspaper, citing government data.
The data suggests that although Canada maintains its leadership position as the No. 1 exporter to Germany, it’s being increasingly challenged by other countries, Alfredo Pascual, vice president of investment analysis at Seed Innovations, told MJBizDaily.
After Canada, the top suppliers to Germany in 2021 were Denmark (3,726 kilograms, or 18.1%), Netherlands (3,724 kilograms, or 18%) and Portugal (2,413 kilograms, or 11.7%).
Another reason for Canada’s diminishing role in Germany’s import mix might stem from some Canadian companies shifting production from their facilities s to Europe.
Edmonton, Alberta-based Aurora Cannabis had been supplying the German market primarily from Canada.
But the receipt of European Union-Good Manufacturing Practice (GMP) certification for its Aurora Nordic facility in Denmark on Sept. 11, 2020, allowed the company “to transition the supply of product destined for the EU markets from Canadian facilities to Nordic,” according to a regulatory filing.
A spokesperson confirmed that the majority of Aurora’s marijuana in Germany is now imported from Denmark.
Aurora shipped medical cannabis from Denmark to Germany for the first time in early 2021.
Aurora also holds one of the three licenses for medical cannabis production in Germany, and its EU-GMP-certified facility there, called Aurora Leuna, opened in July, meaning a limited amount of German demand will be met by Aurora’s facility there.
“With our experienced team, Aurora is well-positioned for future growth in the German market, and to capture opportunities in recreational markets in Europe, pending legalization,” the Aurora spokesperson said.
Axel Gille, president of Aurora Europe, said the company is a leading supplier of in Germany, “with the No. 2 position in medical flower sales and two of the top three bestselling dried-flower products.”
Growth impressive, not exponential
Businesses eyeing the German import market are warned against buying into any forecasts of exponential growth.
The German government data shows that imports dropped meaningfully in the final quarter in three of the past five years.
“While that may sound disappointing to those who were expecting unstoppable exponential growth, it’s still impressive to see that a market that started with less than two metric tons of imports in 2017 grew to over 20 tons imported in 2021,” Pascual said.
Pablo Zuanic, an analyst with New York-based investment banking firm Cantor Fitzgerald, estimates the German medical market will reach 300 million euros ($301 million) by the end of this year.
However, Germany does not publish reliable figures on legal cannabis sales, unlike Canada, leaving analysts and researchers to piece together bits of data.
The analyst also noted that past predictions have been well off the mark, citing a 2018 report by London-based Prohibition Partners that had projected a 1 billion-euro ($1.1 billion) medical market in Germany by 2020 and a forecast by Colorado-based BDS Analytics of an 800 million-euro market by 2022.
Zuanic’s report noted the German market “remains rather undeveloped” and has room for growth.
“What is the outlook for the German medical market? We think the out-of-pocket segment may migrate to the rec market, while the reimbursed (from health insurance) segment could continue to grow despite rec legalization,” according to the report.
Zuanic calculated Germany’s medical flower market to be running at 13 tons annually at an average price of 13 euros per gram overall, or 16 euros per gram for the reimbursed segment and 10 euros per gram for the out-of-pocket segment.
The extracts segment is estimated to be worth 80 million euros; the dronabinol segment is flat to declining, at 20 million euros.
Germany’s plan to legalize recreational cannabis is expected to have an unknown impact on the medical market.
Zuanic’s report asks: “Are we putting too much attention on Germany, a market that we estimate has, at best, 300 million euros in medical cannabis sales at present?”
The answer, according to the report, “will come down to the structure of the future German rec cannabis market, which will determine its size and profitability.”
Source: https://mjbizdaily.com/german-cannabis-imports-growing-as-canadas-leading-share-wanes/
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy